<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01590680</url>
  </required_header>
  <id_info>
    <org_study_id>JDI2007-01</org_study_id>
    <nct_id>NCT01590680</nct_id>
  </id_info>
  <brief_title>Expanded Access Protocol Using 131I-MIBG</brief_title>
  <official_title>An Open Label, Expanded Access Protocol Using 131I-metaiodobenzylguanidine (131I-MIBG) Therapy in Patients With Refractory Neuroblastoma, Pheochromocytoma, or Paraganglioma (Not Eligible for Approved Treatment)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jubilant DraxImage Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jubilant DraxImage Inc.</source>
  <brief_summary>
    <textblock>
      Protocol JDI2007-01 is an Expanded Access Protocol with therapeutic 131I-MIBG for patients
      with neuroblastoma or pheochromocytoma / paraganglioma, who otherwise do not qualify for
      available treatments, or where approved treatment is not commercially available.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Objectives:

        -  To provide 131I-MIBG for compassionate use in patients with neuroblastoma, who otherwise
           do not qualify for inclusion or cannot participate in the sponsor's pivotal Phase II,
           FDA-approved, clinical trial.

        -  To provide 131I-MIBG for compassionate use in patients with neuroblastoma in the absence
           of a commercially available FDA approved product for the indication.

        -  Provide palliative therapy with 131I-MIBG for patients with advanced neuroblastoma.

        -  To provide alternative therapeutic 131I-MIBG options for patients with pheochromocytoma
           / paraganglioma, not qualifying for FDA-approved MIBG treatment.

        -  To provide alternative therapeutic 131I-MIBG options for patients with pheochromocytoma
           / paraganglioma, in the absence of a commercially available FDA-approved product for
           that indication.

        -  Gain more information about acute and late toxicity of 131I-MIBG therapy for patients
           with refractory neuroblastoma, pheochromocytoma, or paraganglioma.

      Patients will receive a therapeutic dose at the investigator's discretion (5-18 mCi/kg).
      However, a dose of 12 mCi/kg or higher requires stored stem cells. Patients may be eligible
      for additional 131I-MIBG treatments (up to a cumulative total of 3 treatments) if they meet
      certain criteria.

      Treatments with 131I-MIBG must be separated by a minimum of six weeks from previous 131I-MIBG
      therapy. Post-treatment evaluation will be performed 5-9 weeks (35-63 days) post treatment,
      and patients will be followed every 6 months until 2 years from therapy. All patients will
      have toxicity monitoring for 2 years following 131I-MIBG therapy, or until going off study.
    </textblock>
  </detailed_description>
  <overall_status>Available</overall_status>
  <study_type>Expanded Access</study_type>
  <condition>Neuroblastoma</condition>
  <condition>Pheochromocytoma</condition>
  <condition>Paraganglioma</condition>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>I-131 MIBG</intervention_name>
    <description>The therapeutic dose (5-18 mCi/kg at investigator's discretion; any dose ≥12 mCi/kg requires stored stem cells) will be diluted in normal saline, and will be infused intravenously over 90-120 minutes.</description>
    <other_name>I-131 Iobenguane</other_name>
    <other_name>I-131 meta-iodobenzylguanidine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION CRITERIA:

          1. Diagnosis: Refractory or relapsed neuroblastoma with original diagnosis based on tumor
             histopathology or elevated urine catecholamines with typical tumor cells in the bone
             marrow, OR pheochromocytoma or paraganglioma (less than 12 years of age) not amenable
             to curative surgery.

          2. Age ≥12 months and able to cooperate with radiation safety restrictions during therapy
             period with/without pharmacologic anxiolysis.

          3. Disease status: Failure to respond to standard therapy (usually combination
             chemotherapy with or without radiation and surgery) or development of progressive
             disease at any time (any new lesion or an increase in size of &gt;25% of a pre-existing
             lesion). Disease evaluation must be completed within 8 weeks of study entry. If
             possible, the disease evaluation should take place subsequent to any intervening
             therapy; if intervening therapy does occur, evaluations should be done as clinically
             indicated. If patient has received prior treatment with MIBG, they must have a
             response or stable disease after the most recent MIBG infusion. Patient may have PD
             after showing an initial response to MIBG therapy (at [or around] the day 35-63
             post-MIBG therapy evaluation).

          4. Stem cells: Patients must have a hematopoietic stem cell product available for
             re-infusion after 131I-MIBG treatment at doses of 12 mCi/kg. If no stem cells are
             available, then the dose of 131I-MIBG should be &lt;12 mCi/kg.

          5. Prior Therapy: Patients may enter this study with or without re-induction therapy for
             recurrent tumor. Patients must have fully recovered from the toxic effects of any
             prior therapy, meeting the following criteria:

               1. At least 2 weeks should have elapsed since any anti-tumor therapy and the patient
                  must meet certain hematologic criteria.

               2. 3 months should have elapsed in the case of completing external beam radiation
                  for total abdominal, whole lung, total body irradiation (spot irradiation to
                  skull-based metastases is NOT a contraindication). Patients who receive localized
                  emergency radiation to sites of life-threatening or function-threatening disease
                  prior to or immediately after establishment of the definitive diagnosis are not
                  contraindicated for treatment on this protocol.

               3. Cytokine therapy (e.g. G-CSF, GM-CSF, IL-6, erythropoietin) must be discontinued
                  a minimum of 24 hours prior to 131I-MIBG therapy.

               4. Minimum of six weeks from previous 131I-MIBG therapy.

               5. The lifetime cumulative injected activity should be evaluated by the Investigator
                  on a case-by-case basis with special attention to any recovery from past
                  131I-MIBG dose(s).

               6. For patients who received a stem cell infusion for a previous 131I-MIBG therapy
                  but do NOT have remaining stored stem cells:

             i. If the stem cell reinfusion was protocol driven but not based upon the development
             of profound cytopenias (e.g. automatic stem cell reinfusion on Day 14), the patient is
             eligible for retreatment with MIBG at a dose &lt;12 mCi/kg at the investigators
             discretion; ii. If the stem cell reinfusion was given based upon the development of
             profound cytopenias, decisions for re-treatment with 131I-MIBG will require a
             case-by-case evaluation by the Investigator.

          6. Organ Function:

               1. Liver function: Bilirubin ≤ 2x upper limit of normal; AST/ALT ≤ 10x upper limit
                  of normal.

               2. Kidney function:

             i. Serum Creatinine ≤ 2x upper limit of normal OR ii. 24-hr creatinine clearance OR
             GFR ≥ 60 ml/min/1.73m2.

             c. Hematologic Criteria: ANC ≥750/uL; Platelets ≥ 50,000/uL without transfusion if
             stem cells are not available (ANC ≥ 500 and any platelet count allowed if stem cells
             available). Patient must be off myeloid growth factors for at least 24 hours. If the
             patient has received prior treatment with MIBG, they may be thrombocytopenic, but
             requiring no more than 2 platelet transfusions per week to maintain counts above
             20,000/uL. Hemoglobin must be ≥ 10gm/dL (transfusion allowed) regardless of stored
             stem cell availability.

             d. Normal lung function, as manifested by no dyspnea at rest or exercise intolerance,
             no oxygen requirement.

             e. No clinically significant cardiac dysfunction.

          7. Signed informed consent/assent has been obtained.

        EXCLUSION CRITERIA:

          1. Patients 12 years and older with iobenguane scan positive, unresectable, locally
             advanced or metastatic pheochromocytoma or paraganglioma and marketed product is
             available.

          2. Patients eligible for the Phase II (OPTIMUM) trial.

          3. Patients with disease of any major organ system that would compromise their ability to
             withstand therapy. Any significant organ impairment should be discussed with the
             Principal Investigator prior to patient entry.

          4. Because of the teratogenic potential of the study medications, no patients who are
             pregnant or lactating will be allowed. Patients of childbearing potential, who are
             sexually active, must practice an effective method of birth control while
             participating on this study, to avoid possible damage to the fetus . [e.g.
             intrauterine device, double-barrier method (i.e., diaphragm, or a cervical cap) with
             intravaginal spermicidal foam, cream or gel], or male partner sterilization throughout
             the study].

          5. Patients who are on hemodialysis

          6. Proteinuria, in the absence of urinary infection, within 4 weeks prior to the planned
             treatment date is a relative contraindication to receiving therapy for patients with
             pheochromocytoma/paraganglioma. Patients with pheochromocytoma/paraganglioma with any
             clinically significant proteinuria must have a 24-hr urine protein determination. If
             proteinuria is confirmed as being above the institutional upper limit of normal, the
             patient is ineligible for MIBG therapy.

          7. Patients with active infections that meet grade 3-4 according to the current version
             of the NCI CTCAE.

          8. Patients with known MIBG-avid parenchymal brain metastases are not eligible. (Patients
             with leptomeningeal or skull-based metastases are eligible.)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Months</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Norman LaFrance, MD,FACP</last_name>
    <phone>215-550-2765</phone>
    <email>Nlafrance@jdi.jubl.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alexandre Brkovic, PhD</last_name>
    <phone>514-694-8220</phone>
    <phone_ext>2464</phone_ext>
    <email>alexandre.brkovic@jdi.jubl.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Children's Hospital Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <last_name>Suzanne B Smolik, RN,MSN</last_name>
      <phone>720-777-6823</phone>
      <email>Suzanne.Smolik@childrenscolorado.org</email>
    </contact>
    <investigator>
      <last_name>Margaret E Macy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Healthcare of Atlanta</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <last_name>Sarah G Carlin, RN,BSN,APHON</last_name>
      <phone>404-785-0083</phone>
      <email>sarah.carlin@choa.org</email>
    </contact>
    <investigator>
      <last_name>Kelly Goldsmith, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Chicago Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <last_name>Melissa Z Marx, MPH</last_name>
      <phone>773-702-2927</phone>
      <email>lzeilner@peds.bsd.uchicago.edu</email>
    </contact>
    <investigator>
      <last_name>Susan L Cohn, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <last_name>Catherine M Clinton, MS</last_name>
      <phone>617-632-5556</phone>
      <email>Catherine_clinton@dfci.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Suzanne Shusterman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Michigan Medicine, University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <last_name>Anne M Ellis, BS</last_name>
      <phone>734-936-5388</phone>
      <email>elanne@med.umich.edu</email>
    </contact>
    <investigator>
      <last_name>Gregory A Yanik, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>North Carolina Children's Hospital</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <last_name>Juanita Ramirez, BA</last_name>
      <phone>919-966-5785</phone>
      <email>juanita_ramirez@med.unc.edu</email>
    </contact>
    <investigator>
      <last_name>Stuart H Gold, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Carolinas Medical Center/ Levine Children's Hospital</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <last_name>Jontyce Green, RN</last_name>
      <phone>980-442-2356</phone>
      <email>Jontyce.Green@atriumhealth.org</email>
    </contact>
    <investigator>
      <last_name>Javier E Oesterheld, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <last_name>Tyler M Ray, BA</last_name>
      <phone>919-681-9186</phone>
      <email>tyler.ray@duke.edu</email>
    </contact>
    <investigator>
      <last_name>Jessica M Sun, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229-3039</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <last_name>Cancer Referral Line</last_name>
      <phone>513-626-2799</phone>
      <email>cancer@cchmc.org</email>
    </contact>
    <investigator>
      <last_name>Brian D Weiss, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <last_name>Maria Gemino-Borromeo, CCRP</last_name>
      <phone>267-425-1987</phone>
      <email>geminoborm@email.chop.edu</email>
    </contact>
    <investigator>
      <last_name>Yael P Mosse, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UPMC Children's Hospital of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <last_name>WeiPing DeBlasio, MBA,BSN,RN</last_name>
      <phone>412-692-5485</phone>
      <email>WeipingXu.DeBlasio@chp.edu</email>
    </contact>
    <investigator>
      <last_name>Jean M Tersak, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Monroe Carell Jr. Children's Hospital at Vanderbilt</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <last_name>Eugenia DC Owens, BS</last_name>
      <phone>615-343-6169</phone>
      <email>eugenia.owens@vumc.org</email>
    </contact>
    <contact_backup>
      <last_name>Mykala L Heuer, BSN</last_name>
      <phone>615-875-2122</phone>
      <email>mykala.l.heuer@vumc.org</email>
    </contact_backup>
    <investigator>
      <last_name>Carrie L Kitko, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Medical Center Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <last_name>Tanya C Watt, MD</last_name>
      <phone>214-456-2382</phone>
      <email>Tanya.Watt@UTSouthwestern.edu</email>
    </contact>
    <investigator>
      <last_name>Tanya C Watt, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cook Children's Medical Center</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <last_name>Tracey Easley, RN,BSN,CPHON</last_name>
      <phone>682-885-4017</phone>
      <email>Tracey.Easley@cookchildrens.org</email>
    </contact>
    <investigator>
      <last_name>Meaghan M Granger, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine, Texas Children's Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77035</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <last_name>Akudo A Anyanwu, BSN,RN</last_name>
      <phone>832-824-3480</phone>
      <email>aaanyanw@texaschildrens.org</email>
    </contact>
    <investigator>
      <last_name>Jennifer H Foster, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seattle Children's Hospital</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <last_name>Christine Goetz, BA,CCRC</last_name>
      <phone>206-884-1149</phone>
      <email>christine.goetz@seattlechildrens.org</email>
    </contact>
    <investigator>
      <last_name>Navin R Pinto, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin Hospital and Clinics, American Family Children's Hospital</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <last_name>Jenny L Weiland</last_name>
      <phone>608-890-8070</phone>
      <email>PedsHemOncResearch@lists.wisc.edu</email>
    </contact>
    <investigator>
      <last_name>Kenneth B De Santes, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>May 1, 2012</study_first_submitted>
  <study_first_submitted_qc>May 2, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 3, 2012</study_first_posted>
  <last_update_submitted>August 12, 2019</last_update_submitted>
  <last_update_submitted_qc>August 12, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 13, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuroblastoma</mesh_term>
    <mesh_term>Pheochromocytoma</mesh_term>
    <mesh_term>Paraganglioma</mesh_term>
    <mesh_term>Carotid Body Tumor</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>3-Iodobenzylguanidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

